Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Uqora** is a branded oral dietary-supplement product line developed by Uqora for proactive urinary-tract health and reduction of recurrent urinary tract infection risk. The line includes formulations such as drink mixes, capsules, and probiotic products; formulations are not uniform across the brand. D-mannose is a principal ingredient in several Uqora products and is intended to act as a soluble decoy for the *Escherichia coli* type 1 fimbrial adhesin FimH, reducing bacterial attachment to the urinary tract and facilitating urinary clearance. Other formulations may include cranberry extract, vitamin C, curcumin, and Lactobacillus probiotics. A randomized, blinded 180-day study of Uqora supplement regimens in women with recurrent urinary tract infections was registered as NCT04024046 and later terminated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Uqora.